Business

Faron Pharmaceuticals LTD: Holding(s) In Company

TURKU, FI / ACCESS Newswire / May 18, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format ...

articleFaron Pharmaceuticals OyMay 18, 20264/company/faron-pharmaceuticals-oy/news/faron-pharmaceuticals-ltd-holdings-in-company-1
Faron Pharmaceuticals LTD: Holding(s) In Company

About this update from Faron Pharmaceuticals Oy

[{"type":"text","content":"TURKU, FI / ACCESS Newswire / May 18, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)","length":88,"tagName":"p"},{"type":"text","content":"TR-1: Standard form for notification of major holdings","length":54,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"7","rowspan":"1","style":"border:1px solid black;padding:2px 4px;","val":[{"type":"text","content":"NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i","length":120,"tagName":"p"}]}]},{"val":[{"colspan":"7","rowspan":"1","style":"border-bottom-color:black;border-left-color:#DDDDDD;border-right-color:#DDDDDD;border-style:solid;border-top-color:black;border-width:1px;padding:2px 4px;text-align:right;","val":[]}]},{"val":[{"colspan":"3","rowspan":"1","style":"border:1px solid black;padding:2px 4px;","val":[{"type":"text","content":"1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:","length":110,"tagName":"p"}]},{"colspan":"4","rowspan":"1","style":"border:1px solid black;padding:2px 4px;text-align:center;","val":[{"type":"text","content":"Faron Pharmaceuticals Ltd","length":25,"tagName":"p"}]}]},{"val":[{"colspan":"7","rowspan":"1","style":"border:1px solid black;padding:2px 4px;","val":[{"type":"text","content":"1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)","length":103,"tagName":"p"}]}]},{"val":[{"colspan":"6","rowspan":"1","style":"border:1px solid black;padding:2px 4px;","val":[{"type":"text","content":"Non-UK issuer","length":13,"tagName":"p"}]},{"colspan":"1","rowspan":"1","style":"border:1px solid black;padding:2px 4px;text-align:center;","val":[{"type":"text","content":"X","length":1,"tagName":"p"}]}]},{"val":[{"colspan":"7","rowspan":"1","style":"border:1px solid black;padding:2px 4px;","val":[{"type":"text","content":"2. Reason for the notification (please mark the appropriate box or boxes with an "X")","length":95,"tagName":"p"}]}]},{"val":[{"colspan":"6","rowspan":"1","style":"border:1px solid black;padding:2px 4px;","val":[{"type":"text","content":"An acquisition or disposal of voting rights","length":43,"tagName":"p"}]},{"colspan":"1","rowspan":"1","style":"border:1px solid black;padding:2px 4px;text-align:center;","val":[{"type":"text","c...

More updates from Faron Pharmaceuticals Oy

Faron Pharmaceuticalsfinancial instrumentsBlood Cancervoting rightsUnited States of AmericaBlood Cancer United, Inc.person subjectnotification